JP Morgan Chase’s Acadia Pharmaceuticals ACAD Stock Holding History

JP Morgan Chase’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-27,000	Closed	-$415K	–	7363
2024 Q3	$415K	Hold	27,000	–	–	﹤0.01%	5023
2024 Q2	$439K	Sell	27,000 -73,000	-73%	-$1.18M	﹤0.01%	4761
2024 Q1	$1.85M	Buy	+100,000	New	+$2.48M	﹤0.01%	3905
2020 Q1	–	Sell	-29,400	Closed	-$1.26M	–	5241
2019 Q4	$1.26M	Buy	+29,400	New	+$1.28M	﹤0.01%	3689
2019 Q1	–	Sell	-20,000	Closed	-$323K	–	5723
2018 Q4	$323K	Sell	20,000 -65,000	-76%	-$1.26M	﹤0.01%	4356
2018 Q3	$1.76M	Buy	+85,000	New	+$1.34M	﹤0.01%	3543
2016 Q2	–	Sell	-215,700	Closed	-$6.03M	–	4744
2016 Q1	$6.03M	Buy	+215,700	New	+$4.7M	﹤0.01%	2098

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

JP Morgan Chase's ACAD Position: Q2 2026 in Review

JP Morgan Chase reduced its Acadia Pharmaceuticals (ACAD) stake by 11% in Q2 2026, selling an estimated $625K and leaving 234,706 shares worth $6.06M. The position accounts for ﹤0.01% of the portfolio, ranked #3281.

JP Morgan Chase first reported a position in ACAD in Q2 2013 and has held it in 53 quarters since. The position peaked at $72.1M in Q3 2017. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

JP Morgan Chase held 234,706 shares of Acadia Pharmaceuticals worth $6.06M as of Q2 2026.
JP Morgan Chase sold 28,385 Acadia Pharmaceuticals shares in Q2 2026, an estimated $625K.
Acadia Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3281 holding.
JP Morgan Chase first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
JP Morgan Chase's Acadia Pharmaceuticals position peaked at $72.1M in Q3 2017.
354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.